Keros Therapeutics, Inc. (KROS)
11.03
-0.20
(-1.78%)
USD |
NASDAQ |
Aug 28, 16:00
11.05
+0.02
(+0.18%)
After-Hours: 20:00
Keros Therapeutics Cash from Operations (Quarterly) : -20.42M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -20.42M |
| March 31, 2026 | -3.529M |
| December 31, 2025 | -27.29M |
| September 30, 2025 | 3.249M |
| June 30, 2025 | -29.62M |
| March 31, 2025 | 161.17M |
| December 31, 2024 | -46.01M |
| September 30, 2024 | -30.50M |
| June 30, 2024 | -39.80M |
| March 31, 2024 | -44.56M |
| December 31, 2023 | -25.46M |
| September 30, 2023 | -33.98M |
| June 30, 2023 | -30.83M |
| March 31, 2023 | -34.24M |
| December 31, 2022 | -21.44M |
| Date | Value |
|---|---|
| September 30, 2022 | -24.60M |
| June 30, 2022 | -22.59M |
| March 31, 2022 | -1.427M |
| December 31, 2021 | -19.56M |
| September 30, 2021 | -14.44M |
| June 30, 2021 | -17.64M |
| March 31, 2021 | -10.50M |
| December 31, 2020 | -7.991M |
| September 30, 2020 | -10.86M |
| June 30, 2020 | -9.927M |
| March 31, 2020 | -8.12M |
| December 31, 2019 | -5.498M |
| September 30, 2019 | -2.955M |
| June 30, 2019 | -5.032M |
| March 31, 2019 | -2.513M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Incyte Corp. | 507.66M |
| Nurix Therapeutics, Inc. | -96.57M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.155M |
| Cash from Financing (Quarterly) | -3.315M |
| Free Cash Flow | -48.49M |
| Free Cash Flow Per Share (Quarterly) | -1.039 |
| Free Cash Flow to Equity (Quarterly) | -19.99M |
| Free Cash Flow to Firm (Quarterly) | -20.58M |
| Free Cash Flow Yield | -16.39% |